C57BL/6JCya-Igsf9em1/Cya
Common Name:
Igsf9-KO
Product ID:
S-KO-18990
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Igsf9-KO
Strain ID
KOCMP-93842-Igsf9-B6J-VB
Gene Name
Product ID
S-KO-18990
Gene Alias
644ETD8; Dasm1; Kiaa1355-hp; NRT1; Ncaml; mKIAA1355
Background
C57BL/6JCya
NCBI ID
Modification
Conventional knockout
Chromosome
1
Phenotype
Document
Application
--
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Igsf9em1/Cya mice (Catalog S-KO-18990) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000111235
NCBI RefSeq
NM_033608
Target Region
Exon 4~9
Size of Effective Region
~3.5 kb
Detailed Document
Overview of Gene Research
IgSF9, also known as immunoglobulin superfamily member 9 or Dasm1, belongs to an evolutionarily ancient protein family. Proteins in this family are expressed in the nervous system and have functions similar to neural cell adhesion molecule family proteins, facilitating homophilic cell adhesion, neurite outgrowth and branching, axon guidance, synapse maturation, self-avoidance, and tiling [1]. In addition, they are involved in several disease-related pathways, such as those related to cancer and liver diseases.
In cancer research, IgSF9 has been found to have different roles. In lung cancer, it promotes tumor invasion and metastasis through the GSK-3β/β-catenin mediated epithelial-to-mesenchymal transition (EMT) pathway [2]. In breast cancer, wild-type p53 trans-activates IgSF9, which then inhibits breast cancer metastasis by interacting with focal adhesion kinase (FAK) and inhibiting the FAK/AKT signaling activity [4]. Low expression of IgSF9 is associated with lymphatic vessel invasion, lymph node metastasis, and advanced TNM staging in breast cancer, making it a potential prognostic marker and therapeutic target [5,7]. In endometrial cancer, IgSF9 is overexpressed, and its expression is associated with myometrium invasion and poor prognosis, suggesting it as a new biomarker [9]. Also, in nasopharyngeal carcinoma, IgSF9 is related to prognosis and hypoxia, with down-regulated IgSF9 reducing cell proliferation, migration, and invasion ability [6]. In terms of its role in the immune system, IgSF9 is an immune checkpoint regulator that suppresses T-cell activation in cancer. Anti-IgSF9 antibody treatment can inhibit tumor growth and enhance the efficacy of anti-programmed cell death protein 1 immunotherapy [3]. Additionally, IgSF9 is among the top differentially expressed proteins associated with both liver steatosis and fibrosis in people living with HIV [8].
In conclusion, IgSF9 plays crucial roles in both neural development-related biological processes and multiple disease conditions, especially in various cancers and liver diseases. Studies on IgSF9 using different research models, including those involving loss-of-function experiments, have provided valuable insights into its functions and potential as a biomarker or therapeutic target in these disease areas.
References：
1. Hansen, Maria, Walmod, Peter Schledermann. 2013. IGSF9 family proteins. In Neurochemical research, 38, 1236-51. doi:10.1007/s11064-013-0999-y. https://pubmed.ncbi.nlm.nih.gov/23417431/
2. Luan, Huiwen, Wang, Ting, Li, Fangmin, Wang, Yaopeng, Li, Zunling. 2024. IGSF9 promotes tumor invasion and metastasis through GSK-3β/β-catenin mediated EMT in lung cancer. In Neoplasia (New York, N.Y.), 58, 101067. doi:10.1016/j.neo.2024.101067. https://pubmed.ncbi.nlm.nih.gov/39383800/
3. Liu, Yifan, Wang, Hongying, Zhao, Xinyu, Wang, Yaopeng, Li, Zunling. . Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti-PD-1 Immunotherapy. In Cancer research, 83, 3385-3399. doi:10.1158/0008-5472.CAN-22-3115. https://pubmed.ncbi.nlm.nih.gov/37506192/
4. Li, Yaohua, Deng, Yiran, Zhao, Yannan, Xu, Yingying, Chen, She. 2022. Immunoglobulin superfamily 9 (IGSF9) is trans-activated by p53, inhibits breast cancer metastasis via FAK. In Oncogene, 41, 4658-4672. doi:10.1038/s41388-022-02459-8. https://pubmed.ncbi.nlm.nih.gov/36088502/
5. Han, Yunwei, Fu, Yiru, Shi, Qianqian, Niu, Chen, Fu, Li. 2022. The ALDH2, IGSF9, and PRDM16 Proteins as Predictive Biomarkers for Prognosis in Breast Cancer. In Clinical breast cancer, 23, e140-e150. doi:10.1016/j.clbc.2022.12.009. https://pubmed.ncbi.nlm.nih.gov/36639264/
6. Huang, Donglan, Liu, Qianqian, Zhang, Weijun, Yuan, Yawei, Deng, Min. 2020. Identified IGSF9 association with prognosis and hypoxia in nasopharyngeal carcinoma by bioinformatics analysis. In Cancer cell international, 20, 498. doi:10.1186/s12935-020-01587-z. https://pubmed.ncbi.nlm.nih.gov/33061850/
7. Shi, Qianqian, Shao, Kang, Jia, Hongqin, Li, Guibo, Fu, Li. 2022. Genomic alterations and evolution of cell clusters in metastatic invasive micropapillary carcinoma of the breast. In Nature communications, 13, 111. doi:10.1038/s41467-021-27794-4. https://pubmed.ncbi.nlm.nih.gov/35013309/
8. van Eekeren, Louise E, de Mast, Quirijn, Meeder, Elise M G, Tjwa, Eric T T L, Joosten, Leo A B. 2024. Plasma proteomic signatures of liver steatosis and fibrosis in people living with HIV: a cross-sectional study. In EBioMedicine, 109, 105407. doi:10.1016/j.ebiom.2024.105407. https://pubmed.ncbi.nlm.nih.gov/39426127/
9. Shi, Zonggao, Li, Chunyan, Tarwater, Laura, Chandrashekar, Darshan S, Stack, M Sharon. 2018. RNA-seq Reveals the Overexpression of IGSF9 in Endometrial Cancer. In Journal of oncology, 2018, 2439527. doi:10.1155/2018/2439527. https://pubmed.ncbi.nlm.nih.gov/29666643/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen